Abstract:Abstract 4815 Introduction: Acute myeloid leukemia (AML) is the most common type of adult leukemia for which cytosine arabinoside(Ara-C)-based chemotherapy is the main treatment. However, there is a significant difference in treatment response and survival, especially among large groups of patients with the same disease classification. Single nucleotide polymorphisms within the nucleotide excision repair pathway may alter the susceptibility of leukemia cells to chemotherapy. We investigated the role of six single nucleotide polymorphisms (ERCC5rs76871136, ERCC5rs77569659, ERCC5rs873601, XPCrs2228000, XPCrs2228001, and XPCrs1870134) within the nucleotide excision repair pathway on the outcome of patients with AML treated with cytosine arabinoside-based chemotherapy. Methods: One hundred fifty-one patients with AML in a Chinese population were enrolled in this study. Patients diagnosed with other cancers or other hematological malignancies were excluded in this study. This study was approved by the ethics committee of Southeast University in compliance with Chinese guidelines for blood donation, and informed consent for genetic analysis was obtained from all participants according to the Declaration of Helsinki. All patients received Ara-C-based standard induction chemotherapy regimens. Patients were divided into three groups, according to cytogenetic risk. Moreover, the evaluation standard of these patients were evaluated by age(£40 years, 40–60 years, and 360 years), WBC (>50 ′ 109/L vs. £50 ′ 109/L), hemoglobin level (>100 g/L vs. £100 g/L), and platelet count (>60 ′ 109/L vs. £60 ′ 109/L). Genotypes were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Deviations from the Hardy–Weinberg equilibrium for genotypes and haplotype frequencies as well as haplotype–trait associations were assessed with Pearson's c2 analysis using SHEsis. Once the expected number in any cell was less than five, demographic and clinical data across genotypes were compared using Pearson's c2analysis or Fisher's exact test. Significant genotypic differences among the different responders were calculated using Pearson's c2analysis. P <0.05 was considered statistically significant. We estimated the relative risk of responding to treatment with the genotypes as odds ratio(OR) and 95% confidence intervals(95%CI) using conditional logistic regression with adjustment for the effects of covariates. All statistical tests were two-sided and performed using SPSS 17.0. Results: Genotype frequencies for the polymorphisms were found to be in Hardy–Weinberg equilibrium. The results indicated that the distribution of three genotypes of XPCrs1870134 significantly differed among the cytogenetic risk groups (P = 0.04). The frequency of the CC genotype of XPCrs2228001 was significantly higher in male patients than in female patients (P = 0.03), whereas that of the CC genotype of XPCrs2228000 was significantly higher in patients with a hemoglobin level of 100 g/L or less compared with those who had a hemoglobin level greater than 100 g/L (P = 0.039).Moreover, patients carrying at least one variant allele (XPCrs2228001AA+CC) were more likely to respond better than those who did not carry a variant. However, no significant association was detected between polymorphisms in ERCC5 and treatment response. Conclusions: These findings suggest that XPC polymorphisms are important markers for the outcome of patients with AML in the Chinese population. Disclosures: No relevant conflicts of interest to declare.

[Relationship Between RAD51-g135C and XRCC3-C241T Polymorphisms and Prognosis of Inv (16)/ T(16;16) (Cbfbeta-Myh11) Acute Myeloid Leukemia].

RAD51 and XRCC3 Polymorphisms: Impact on the Risk and Treatment Outcomes of De Novo Inv(16) or T(16;16)/cbfβ–myh11(+) Acute Myeloid Leukemia

[Polymorphisms of RAD51(G135C) and XRCC3(C241T) Genes and Correlations Thereof with Prognosis and Clinical Outcomes of Acute Myeloid Leukemia].

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Unusual Findings Of Acute Myeloid Leukemia With Inv(3)(Q21q26.2) Or T(3;3)(Q21;Q26.2): A Multicenter Study

Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Association of WT1 Rs16754 Polymorphism with Clinical Features and Prognosis in Patients with Acute Myeloid Leukemia

Polymorphisms in XRCC5, XRCC6, XRCC7 Genes Are Involved in DNA Double-Strand Breaks(dsbs) Repair Associated with the Risk of Acute Myeloid Leukemia(aml) in Chinese Population

Clinical Analysis of Acute Myeloid Leukemia with Inv(16)/t(16;16)

Polymorphisms in XPC Provide Prognostic Information in Acute Myeloid Leukemia

FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.

Genetic Variations Of Dna Repair Genes And Their Prognostic Significance In Patients With Acute Myeloid Leukemia

[Correlation Between MDR1 Genetic Polymorphism and Prognosis in Acute Myeloid Leukemia].

Mutation Topography and Risk Stratification for De Novo Acute Myeloid Leukaemia with Normal Cytogenetics and No Nucleophosmin 1 (NPM1) Mutation or Fms‐like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3‐ITD)

PF218 DDX11 MUTATIONS AND CLONAL TRAJECTORY PATTERNS IN ADULTS WITH CYTOGENETICALLY-NORMAL ACUTE MYELOID LEUKEMIA

Clinical Characteristics and Prognostic Factors Analysis of Core Binding Factor Acute Myeloid Leukemia in Real World.

Kit Mutation Versus Mrd, Which is More Important to Predict Relapse of Acute Myeloid Leukemia with T (8;21)?

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

The Rs9909659g/A Polymorphisms of the Stat3 Gene Provide Prognostic Information in Acute Myeloid Leukemia

Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.